View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 15, 2021updated 12 Jul 2022 11:05am

Novartis’ Jakavi improves outcomes in Phase III chronic GvHD trial

Jakavi led to substantial improvements in ORR at 24 weeks, thereby meeting the primary endpoint of the trial.

Novartis has reported positive data from the Phase III REACH3 clinical trial, showing that Jakavi (ruxolitinib) substantially enhanced outcomes in steroid-refractory/dependent chronic graft-versus-host disease (GvHD) patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An oral, JAK 1 and JAK 2 tyrosine kinases inhibitor, ruxolitinib was licensed by Novartis from Incyte for development and marketing outside the US.

A fatal disease associated with the long-term complication of stem cell transplants, chronic GvHD can impact various organs. Nearly 50% of patients develop a refractory condition to or dependence on first-line steroids.

According to the results from the REACH3 trial, Jakavi offered substantial improvements in an overall response rate (ORR) at week 24, meeting the trial’s primary goal.

In the Jakavi arm, 76.4% of subjects had a best overall response (BOR) rate at any time up to week 24 versus 60.4% of those receiving the best available therapy (BAT).

Jakavi was shown to offer statistically significant and clinically meaningful improvements in longer failure-free survival (FFS) compared with the BAT arm.

Subjects in the Jakavi arm had superior improvements in self-reported symptoms versus those in the BAT arm.

Furthermore, data from a new subgroup analysis showed that subjects receiving Jakavi experienced improved outcomes irrespective of their organs involved at the baseline.

No new safety signals linked to the drug were reported in the Phase III trial. Adverse events related to Jakavi were in line with its mechanism of action and the already known safety profile.

Incyte sought approval from the US Food and Drug Administration for ruxolitinib to be marketed as Jakafi to treat steroid-refractory chronic GvHD. The application is presently under review.

Novartis’ regulatory filings outside the US for Jakavi for acute and chronic GvHD are progressing.

Novartis oncology president Susanne Schaffert said: “These new Jakavi data underscore its potential benefits and the importance of making it available to patients at risk for an all-too-common and life-threatening complication of stem cell transplants.

“We are pleased that regulatory submissions are underway and will continue to work toward wide accessibility of this important new medicine for GvHD.”

Last month, Novartis reported positive data from two Phase III trials, which further demonstrated the use of Zolgensma for treating spinal muscular atrophy in paediatric patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena